Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma.
Allergology Department, Centre de l'Asthme et des Allergies, Hôpital d'Enfants Armand-Trousseau - 26, Paris Cedex 12, France; INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Sorbonne Universités, UPMC Univ Paris 06, Paris, France.
Nathalie
N
Lambert
Tamazoust
T
Guiddir
Flore
F
Amat
Jocelyne
J
Just
D000293:Adolescent; D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002648:Child; D003888:Desensitization, Immunologic / Q000379:methods*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D000069444:Omalizumab; D065631:Rhinitis, Allergic / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome; D055815:Young Adult
D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab
asthma; omalizumab; subcutaneous allergen-specific immunotherapy